FDA names drugmakers potentially acting to delay cheap generics

(Reuters) - The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Johnson & Johnson, Gilead Sciences and Novartis AG, who the regulator says are potentially blocking access to samples of their drugs to delay gen...

More From BioPortfolio on "FDA names drugmakers potentially acting to delay cheap generics"

Relevant Topics

The Top 100 Pharmaceutical CompaniesTop 10 biotech and pharmaceutical companies worldwide based on market value in 2015
2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars)
Johnson & Johnson, U.S.
74...

NovartisNovartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...